[{"id":"ba0b6173-d6ba-4d9f-b7a6-14e36795d0f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02337985","created_at":"2021-01-18T11:06:20.660Z","updated_at":"2025-02-25T16:36:30.633Z","phase":"Phase 1","brief_title":"Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02337985","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/20/2015","start_date":" 11/20/2015","primary_txt":" Primary completion: 10/02/2025","primary_completion_date":" 10/02/2025","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"},{"id":"91851c6c-8544-4437-8d34-90b527fa0625","acronym":"TUC-TOC","url":"https://clinicaltrials.gov/study/NCT05955170","created_at":"2023-07-21T16:11:20.614Z","updated_at":"2024-07-02T16:34:37.017Z","phase":"Phase 2","brief_title":"Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05955170 - TUC-TOC","lead_sponsor":"Institut Curie","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • etoposide oral"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/19/2023","start_date":" 12/19/2023","primary_txt":" Primary completion: 12/19/2026","primary_completion_date":" 12/19/2026","study_txt":" Completion: 12/19/2027","study_completion_date":" 12/19/2027","last_update_posted":"2024-06-07"},{"id":"ff9901cb-527b-445b-8ed0-9ab957156b38","acronym":"","url":"https://clinicaltrials.gov/study/NCT06436144","created_at":"2024-06-01T04:16:47.095Z","updated_at":"2024-07-02T16:35:00.145Z","phase":"Phase 2","brief_title":"Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC","source_id_and_acronym":"NCT06436144","lead_sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • etoposide oral"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-30"},{"id":"ba959a30-fc13-41fa-bfe2-ed5b6c5cbb41","acronym":"","url":"https://clinicaltrials.gov/study/NCT02342782","created_at":"2021-01-18T11:08:11.471Z","updated_at":"2024-07-02T16:35:14.106Z","phase":"Phase 1","brief_title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02342782","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK • CD34","pipe":"","alterations":" ","tags":["ALK • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • etoposide oral • carmustine • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"8d4ab3d0-11ea-458b-b094-6941a461f5b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04217798","created_at":"2021-01-18T20:32:03.574Z","updated_at":"2024-07-02T16:36:25.007Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04217798","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • etoposide oral"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2021-09-01"},{"id":"dbb49f59-b159-4f28-b76a-1ba323a91171","acronym":"","url":"https://clinicaltrials.gov/study/NCT03535961","created_at":"2021-01-18T17:25:00.579Z","updated_at":"2024-07-02T16:36:37.918Z","phase":"Phase 2","brief_title":"Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03535961","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • etoposide oral"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2020-12-02"},{"id":"f3b3c686-6d60-4f13-aca8-b9ecc2ea4fdc","acronym":"PEPI","url":"https://clinicaltrials.gov/study/NCT00578864","created_at":"2021-01-18T02:07:21.218Z","updated_at":"2024-07-02T16:36:47.548Z","phase":"Phase 2","brief_title":"Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma","source_id_and_acronym":"NCT00578864 - PEPI","lead_sponsor":"Baylor College of Medicine","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide oral • melphalan • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/01/2007","start_date":" 03/01/2007","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2020-03-27"},{"id":"ed72a489-9c5c-48a1-8c86-d6edaba3e6b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03707847","created_at":"2021-01-18T18:10:42.303Z","updated_at":"2024-07-02T16:37:06.048Z","phase":"Phase 4","brief_title":"Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL","source_id_and_acronym":"NCT03707847","lead_sponsor":"Mingzhi Zhang","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • etoposide oral"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2018-10-16"},{"id":"2be76ab5-31fd-4803-92cb-50010854ddf0","acronym":"AREN0321","url":"https://clinicaltrials.gov/study/NCT00335556","created_at":"2021-01-18T01:09:32.287Z","updated_at":"2024-07-02T16:37:19.723Z","phase":"Phase 2","brief_title":"Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors","source_id_and_acronym":"NCT00335556 - AREN0321","lead_sponsor":"Children's Oncology Group","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • etoposide oral • vincristine • dactinomycin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 291","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2017-07-21"}]